Rojo, Federico

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation

PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling

Cited by 1,381

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer

Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 895

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 829

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C.-L., Skhinas, J. N., Collot, R., Yang, J., Harvey, K., et al. (2018) · Nature Communications

Hedgehog Signaling Pathway StudiesCancer Cells and Metastasis

Cited by 437

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Pairo-Castineira, E., Rawlik, K., Bretherick, A. D., Qi, T., Wu, Y., Nassiri, I., McConkey, G. A., Zechner, M., Klaric, L., Griffiths, F., et al. (2023) · Nature

Genetic Associations and EpidemiologyCOVID-19 Clinical Research Studies

Cited by 225

Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study

Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez-Braun, E., Eugenia Vega-Villegas, M., Senger, S., et al. (2010) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 110

Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer

Cristóbal, I., Rincón, R., Manso, R., Caramés, C., Zazo, S., Madoz-Gúrpide, J., Rojo, F., & García-Foncillas, J. (2015) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesProtein Tyrosine Phosphatases

Cited by 78

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients

Alonso, V., Escudero, P., Fernández-Martos, C., Salud, A., Méndez, M., Gallego, J., Rodriguez, J.-R., Martín-Richard, M., Fernández-Plana, J., Manzano, H., et al. (2018) · Neoplasia

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 10